Last A$0.28 AUD
Change Today -0.005 / -1.72%
Volume 20.9K
VLA On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 1:56 AM 05/21/13 All times are local (Market data is delayed by at least 15 minutes).

viralytics ltd (VLA) Snapshot

Open
A$0.28
Previous Close
A$0.29
Day High
A$0.28
Day Low
A$0.28
52 Week High
10/29/12 - A$0.47
52 Week Low
09/19/12 - A$0.20
Market Cap
24.9M
Average Volume 10 Days
52.1K
EPS TTM
A$-0.07
Shares Outstanding
87.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VIRALYTICS LTD (VLA)

Related News

No related news articles were found.

viralytics ltd (VLA) Related Businessweek News

No Related Businessweek News Found

viralytics ltd (VLA) Details

Viralytics Limited, a biotechnology company, engages in the development of oncolytic virotherapy for the treatment of a range of cancers principally in Australia. The company primarily develops CAVATAK, an oncolytic virus that lyses cancer cells, which is in a Phase II clinical trial for the treatment of late stage melanoma; has completed a Phase I single dose-escalation intravenous study for the treatment of melanoma, breast, prostate, and colon cancers; and has completed a multi dose intratumoral trial for the treatment of late stage head and neck cancers. It also develops EVATAK drug, which is in a preclinical stage for the treatment of various cancers. The company was formerly known as Psiron Limited and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Pymble, Australia.

17 Employees
Last Reported Date: 08/31/12

viralytics ltd (VLA) Top Compensated Officers

Chief Scientific Officer
Total Annual Compensation: A$175.3K
Compensation as of Fiscal Year 2012.

viralytics ltd (VLA) Key Developments

Viralytics Limited Announces Executive Changes

Viralytics Limited advised that Mr. Paul Hopper will cease to act as Executive Chairman on April 30, 2013 following the appointment of Dr. Malcolm McCol as Chief Executive Officer and an effective transition of responsibilities to Dr. McCol. Mr. Hopper will resume his role as Non-Executive Chairman effective May 1, 2013.

Viralytics Limited Announces Relocation of Principal Administrative Office

Viralytics Limited advised that effective on 27 February 2013, the company's principal administrative office has moved to Suite 305, 66 Hunter St, Sydney NSW 2000.

Viralytics Limited Reports Earnings Results for the Six Months Ended December 31, 2012

Viralytics Limited reported earnings results for the six months ended December 31, 2012. For the period, the company reported total income of AUD 720,455 against AUD 129,254 a year ago. Loss from ordinary activities before income tax was AUD 2,511,315 against AUD 2,714,998 a year ago. Comprehensive income was AUD 2,511,315 or 3.3 cents diluted loss per share against AUD 2,714,998 or 4.6 cents diluted loss per share a year ago. Net cash used in operating activities was AUD 1,235,266 and purchase of Plant and equipment was AUD 6,445 against net cash used in operating activities of AUD 1,725,542 and purchase of Plant and equipment of AUD 9,082 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VLA:AU A$0.28 AUD -0.005

VLA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VLA.
View Industry Companies
 

Industry Analysis

VLA

Industry Average

Valuation VLA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VIRALYTICS LTD, please visit www.viralytics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.